Metraipolis › archive › dc_eef8d17b9769

Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study — Europe PMC PMID:41557039

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41557039
DOI
10.1007/s10549-[numero omesso]-4
License (as archived)
solo-consultazione
Archived
2026-11-06T16:38:20.873Z
SHA-256 of the archived text
f0633d79cfc782f10536376c4021cc9abe05bcb7bab8e8411f32ce9b7cc8ef9b
Stable URL of this page
https://metraipolis.com/documento/dc_eef8d17b9769

How to cite

Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study — Europe PMC PMID:41557039 — Europe PMC (en), https://europepmc.org/article/MED/41557039 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eef8d17b9769 (Metraipolis archive dc_eef8d17b9769, sha256 f0633d79cfc782f10536376c4021cc9abe05bcb7bab8e8411f32ce9b7cc8ef9b)
BibTeX
@misc{dceef8d17b9769,
  title = {Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study — Europe PMC PMID:41557039},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41557039},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eef8d17b9769; sha256 f0633d79cfc782f10536376c4021cc9abe05bcb7bab8e8411f32ce9b7cc8ef9b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41557039. Agents can read the archived copy with the MCP tool read_document.